Farallon Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Farallon Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-501,618	Closed	-$18.9M	–	394
2021 Q1	$18.9M	Buy	501,618 +101,618	+25%	+$2.53M	0.09%	107
2020 Q4	$6.8M	Buy	+400,000	New	+$5.01M	0.04%	113

Farallon Capital Management's FPRX Position: Q2 2021 in Review

Farallon Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 501,618 shares — an estimated $18.9M sold.

Farallon Capital Management first reported a position in FPRX in Q4 2020 and held it in 2 quarters. The position peaked at $18.9M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Farallon Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Farallon Capital Management sold 501,618 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $18.9M.
Farallon Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
Farallon Capital Management's Five Prime Therapeutics, Inc. position peaked at $18.9M in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.